BD (Becton, Dickinson and Company) has announced the global commercial release of new configurations of cell analysers featuring breakthrough spectral and real-time cell imaging technologies, enabling more laboratories in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.
The new BD FACSDiscover A8 Cell Analyzers feature BD SpectralFX Technology, which allows scientists to analyse up to 50 or more characteristics of a single cell with optimal resolution and sensitivity, and BD CellView Image Technology, which enables high-speed imaging, revealing spatial and morphological insights – like the location of a protein within a single cell – that can be visually analysed in real time.
The three- and four-laser additions to the BD FACSDiscover A8 Cell Analyzer portfolio complement the five-laser instrument launched earlier this year, providing more scientists worldwide the opportunity to incorporate industry-leading capabilities in their laboratories. Both versions have the option to start with a free trial of CellView Image Technology and upgrade later via software – giving laboratories further flexibility.
"The BD FACSDiscover A8 Cell Analyzer has become our new standard, changing how our flow cytometry core operates," said Gert Van Isterdael, Head of VIB Flow Core Ghent. "Once you experience the integration of spectral and imaging data, you don't want to go back. It opens a new dimension for our work, helping us see more, understand faster, and enable discoveries that simply weren't possible before. The BD FACSDiscover A8 Cell Analyzer is a game changer, and having more configurations will only make this leading technology more accessible to a wider range of laboratories."
All configurations of the BD FACSDiscover A8 Cell Analyzer feature high-throughput, walkaway automation that enables best-in-class cost-per-insight economics through real-time imaging. The intuitive software makes it easy to manage large datasets and is designed for out-of-the-box standardisation. The analysers also pair seamlessly with the ecosystem of BD FACSDiscover Cell Sorters and BD Reagents. This includes the recently launched BD Horizon RealViolet 828 and RealBlue 824 fluorochromes, pioneering entries into the near-infrared spectrum that, when used with a cell analyser, can unlock new discoveries through spectral flow cytometry.
"In today's complex research landscape, access to leading-edge technologies through flexibility and modularity is crucial, from basic to translational science," said Steve Conly, Worldwide President of BD Biosciences. "Alongside the entire BD ecosystem of sorters, reagents, and informatics, the BD FACSDiscover A8 Cell Analyzer continues to be rapidly adopted by leading biopharmaceutical companies, and now with more entry points, organisations of all sizes can access the same technology."
BD FACSDiscover A8 Cell Analyzers are now available to order through local sales representatives. For researchers facing capital expenditure constraints, flexible financing options are now available. More information is available at www.bdbiosciences.com.